Unnatural Products funding, valuation and investors

Product & use cases

This is a research-stage biotech platform, not a consumer-facing drug product. A representative (illustrative, not hands-on-tested) pharmaceutical partner flow: (1) choose a disease-relevant intracellular or extracellular molecular target that conventional molecules struggle to reach; (2) use UNP's computational and machine-learning design plus chemical expertise to propose ring-shaped macrocyclic peptide variants; (3) synthesize numerous variants with parallel chemistry; (4) screen them experimentally for affinity, potency, cell permeability, selectivity and physicochemical behavior; (5) iterate candidate design and medicinal chemistry while checking safety, stability, metabolic exposure and manufacturability; (6) license or co-develop selected candidates, with investigational new drug-enabling studies, clinical testing and regulatory review handled under the relevant partnership. Inputs are target biology and assay data; outputs are experimentally characterized research compounds, not FDA-approved medicines. The intended buyer is a pharma R&D/BD group seeking differentiated drug leads; verified model includes research collaboration, licensing, development/regulatory milestones and eventual royalties where disclosed. No list price or audited conversion of partnerships into sales is public. Novartis assumes clinical development/manufacturing of its partnered undisclosed cardiovascular program. Argenx plans to combine UNP peptide discovery with its antibody expertise if deal closes.

• Drug-discovery teams seek selectively binding macrocyclic peptides for difficult intracellular targets, experimentally testing permeability and exposure rather than assuming oral availability.
• Pharma partners such as Novartis license preclinical discovery programs with potential development/regulatory/commercial milestones and royalties; these milestone ceilings are not guaranteed payments.
• Argenx plans to retain the Santa Cruz team and use peptide discovery alongside antibody engineering in immunology, contingent on deal closing.

Key facts

• Nov 9 2026: argenx signed definitive agreement to acquire remaining UNP equity. $550M cash on closing plus up to $595M contingent milestones; up to ~$1.15B possible, not realized price. Buyer already owns a minority stake. Expected year-end close, not yet completed.
• The Santa Cruz discovery team is to become argenx's peptide discovery hub after closing; a two-plus-year prior collaboration preceded the acquisition announcement.
• Mar 16 2026: UNP closed $45M Series B led by The Venture Collective, with argenx, Droia Ventures and continuing investors. This is venture equity, not the acquisition payment.
• Dec 19 2023: $32M Series A co-led by Merck Global Health Innovation Fund and ARTIS Ventures. Other earlier seed investment is known from secondary sources but exact cash total isn't independently reconciled in this update. An earlier September 2019 seed was MORE THAN $6M led by ARTIS; together the three announcements disclose MORE THAN $83M of startup equity, not an exact $83M.
• Feb 18 2026: Novartis licensing includes up to $100M IN upfront and pre-IND milestone payments plus up to $1.7B in downstream milestones, with conditional royalties—not guaranteed cash, new equity, nor UNP's acquisition price.
• Research-stage platform; oral availability, target selectivity and clinical benefits require compound-specific preclinical and clinical validation. Company has not disclosed a marketed medicine.

Competitive landscape

Edge: The company's stated differentiation is the continuous design-synthesis-screening loop linking machine learning to high-throughput medicinal chemistry and biological measurements. A durable advantage would require validated oral delivery, efficacy, favorable tox/PK, proprietary target opportunities and scalable synthesis; neither platform volume nor a headline acquisition value alone demonstrates clinical success.

The $550M cash is payable only if the agreed acquisition closes; $595M is conditional on specified development/regulatory milestones. Since argenx already owns a minority stake, headline consideration relates to buying remaining ownership and cannot automatically be equated to all shareholder proceeds or UNP's enterprise value. The Novartis pact is separate and its up-to payments are prospective. Compared with antibodies, macrocycles may offer possibilities for oral dosing or intracellular delivery, but those are compound-specific claims demanding rigorous safety/clinical proof; clinical effectiveness, unit manufacturing economics, program success probabilities, and ultimate payments are unknown. More than 50 employees and four major partnerships are company-reported, not annual recurring revenue.

• PeptiDream adjacent

  Established peptide-discovery and partnering business; compare target access, medicinal chemistry platforms and program maturity, not just peptide terminology.

• Bicycle Therapeutics adjacent

  Bicycle peptide drug programs emphasize tumor targeting and clinical-stage therapeutics; distinct scaffolds and maturity from UNP synthetic macrocycles.

• Other pharma medicinal-chemistry and biologics discovery teams incumbent

  Internal fragment/small-molecule, antibodies and structure-guided chemistry can compete for the same target biology with different permeability, cost and intellectual-property tradeoffs.

Market / IPO context